Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Anesthesiology
|
May 30, 2006
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers
Ashraf Yassen, Erik Olofsen, Raymonda Romberg, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
February 8, 2012
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development
Ashley Strougo, Thomas Eissing, Ashraf Yassen, et al.
Journal of Pain Research
|
April 27, 2012
Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups
Christian Martini, Ashraf Yassen, Erik Olofsen, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 21, 2006
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats
Ashraf Yassen, Jingmin Kan, Erik Olofsen, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 7, 2007
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats
Ashraf Yassen, Jingmin Kan, Erik Olofsen, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 30, 2021
First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
Dirk Thomas, Friederike Kanefendt, Stephan Schwers, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 1, 2022
First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
Bettina Nowotny, Dirk Thomas, Stephan Schwers, et al.
Clinical Pharmacokinetics
|
October 10, 2007
Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers
Ashraf Yassen, Erik Olofsen, Eveline van Dorp, et al.
Research and Practice in Thrombosis and Haemostasis
|
April 24, 2019
BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
Dirk Thomas, Kirstin Thelen, Stefanie Kraff, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 12, 2025
Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events
Ashraf Yassen, Friederike Kanefendt, Jochen Zisowsky, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Anesthesiology
|
May 30, 2006
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers
Ashraf Yassen, Erik Olofsen, Raymonda Romberg, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
February 8, 2012
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development
Ashley Strougo, Thomas Eissing, Ashraf Yassen, et al.
Journal of Pain Research
|
April 27, 2012
Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups
Christian Martini, Ashraf Yassen, Erik Olofsen, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 21, 2006
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats
Ashraf Yassen, Jingmin Kan, Erik Olofsen, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 7, 2007
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats
Ashraf Yassen, Jingmin Kan, Erik Olofsen, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 30, 2021
First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
Dirk Thomas, Friederike Kanefendt, Stephan Schwers, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 1, 2022
First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
Bettina Nowotny, Dirk Thomas, Stephan Schwers, et al.
Clinical Pharmacokinetics
|
October 10, 2007
Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers
Ashraf Yassen, Erik Olofsen, Eveline van Dorp, et al.
Research and Practice in Thrombosis and Haemostasis
|
April 24, 2019
BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
Dirk Thomas, Kirstin Thelen, Stefanie Kraff, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 12, 2025
Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events
Ashraf Yassen, Friederike Kanefendt, Jochen Zisowsky, et al.
Page
of 3